Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway

Abstract

Overexpression of epidermal growth factor receptor (EGFR) and establishment of transforming growth factor α (TGF α)/EGF autocrine system are frequently detected in tumor cells. In addition to mitogenic ability, we demonstrate in this report that EGF protects a human esophageal carcinoma (CE) cell line, CE81T/VGH, from staurosporine-induced apoptosis. The anti-apoptotic signal of EGF is alleviated by a MEK inhibitor PK98059 or an ERK2 dominant negative mutant but not by a phosphatidylinositol-3′-kinase (PI-3K) inhibitor wortmannin. Furthermore, v-raf blocks apoptosis induced by staurosporine. This evidence implies that the survival signal of EGF is mediated via the Raf-MEK-ERK pathway but not the PI3-K pathway. The survival effect of EGF is coincident with the induction of mcl-1, an anti-apoptotic gene in the bcl-2 family. PD98059 also suppresses the induction of Mcl-1 by EGF, implying that EGF may up-regulate Mcl-1 via the MAP kinase pathway. Overexpression of mcl-1 is sufficient to protect against apoptosis, while transfection of a mcl-1 antisense plasmid causes cell death. The expression of mcl-1 antisense plasmid also suppresses the anti-apoptotic effect of EGF. Taken together, these results indicate that EGF may up-regulate Mcl-1 through the MAP kinase pathway to suppress apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Adams JM and Cory S . 1998 Science 281: 1322–1325

  • Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR . 1995 J Biol Chem 270: 27489–27494

  • Altmeyer A, Simmons RC, Krajewski S, Reed JC, Bornkamm GW and Chen-Kiang S . 1997 Immunity 7: 667–677

  • Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod J-J, Mazzei G, Maundrell K, Grambale F, Sadoul R and Martinou J-C . 1997 Science 277: 370–372

  • Basolo F, Serra C, Ciardiello F, Fiore L, Russo J, Campani D, Dolei A, Squartini F and Toniolo A . 1992 Int J Cancer 51: 634–640

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC . 1998 Science 282: 1318–1321

  • Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, Yen JJ-Y and Yang-Yen HF . 1998 Mol Cell Biol 18: 4883–4898

  • Chen SC, Chou CK, Wong FH, Chang C and Hu C . 1991 Cancer Res 51: 1898–1903

  • Collette Y, Razanajaona D, Ghiotto M and Olive D . 1997 Eur J Immunol 27: 3283–3289

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg M . 1997 Cell 91: 231–241

  • del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G . 1997 Science 278: 687–689

  • Dragovich T, Rudin CR and Thompson CB . 1998 Oncogene 17: 3207–3213

  • Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR and Greenberg ME . 1997 Science 275: 661–665

  • Dunn SE, Hardman RA, Kari FW and Barrett JC . 1997 Cancer Res 57: 2687–2693

  • Fabregat I, Sanchez A, Alvarez AM, Nakamura T and Benito M . 1996 FEBS Lett 384: 14–18

  • Fitzpatrick SL, LaChance MP and Schultz GS . 1984 Cancer Res 44: 3442–3447

  • Frost JA, Geppert TD, Cobb MH and Feramisco JR . 1994 Proc Natl Acad Sci USA 91: 3844–3848

  • Geier A, Weiss C, Berry R, Haimsohn M, Hemi R, Malik Z and Karasik A . 1995 J Cell Physiol 163: 570–576

  • Hu C, Hsieh HG, Chien KY, Wang PY, Wang CI, Chen CY, Lo SJ, Wuu KD and Chang C . 1984 JNCI 72: 577–583

  • Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, Miyata M, Oka H, Doki Y and Mori T . 1993 Cancer 71: 2902–2909

  • Kozopas KM, Yang T, Buchan HL, Zhou P and Criag RW . 1993 Proc Natl Acad Sci USA 90: 3516–3520

  • Kulik G, Klippel A and Weber MJ . 1997 Mol Cell Biol 17: 1595–1606

  • Kulik G and Weber MJ . 1998 Mol Cell Biol 18: 6711–6718

  • Liu YC, Chen SC, Chang C, Leu CM and Hu C . 1996 Exp Cell Res 228: 206–211

  • Lu SH, Hsieh LL, Luo FC and Weinstein IB . 1988 Int J Cancer 42: 502–505

  • Merlo GR, Basolo F, Fiore L, Duboc L and Hynes NE . 1995 J Cell Biol 128: 1185–1196

  • Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M and Thompson CB . 1997 Nature 385: 353–357

  • Minshall C, Arkins S, Freund GG and Kelley KW . 1996 J Immunol 156: 939–947

  • Omura S, Sasaki Y, Iwai Y and Takeshima H . 1995 J Antibiot 48: 535–548

  • Osterop APRM, Medema RH, Ouwens DM, Van der Zon GCM, Moller W and Maassen JA . 1994 Biochemistry 33: 7453–7459

  • Ozawa S, Ueda M, Ando N, Abe O and Shimizu N . 1987 Int J Cancer 39: 333–337

  • Ozawa S, Ueda M, Ando N, Shimizu N and Abe O . 1989 Cancer 63: 2169–2173

  • Pang L, Sawada T, Decker SJ and Saltiel AR . 1995 J Biol Chem 270: 13585–13588

  • Parrizas M, Saltiel AR and LeRoith D . 1997 J Biol Chem 272: 154–161

  • Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G and Aaronson SA . 1988 Science 239: 628–631

  • Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds Jr FH and Stephenson JR . 1983 Proc Natl Acad Sci USA 80: 4218–4222

  • Reynolds JE, Li J, Craig RW and Eastman A . 1996 Exp Cell Res 225: 430–436

  • Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A and Craig RW . 1994 Cancer Res 54: 6348–6352

  • Ruegg UT and Burgess GM . 1989 Trends Pharmacol Sci 10: 218–220

  • Sato N, Sakamaki K, Terada N, Arai KI and Miyajima M . 1993 EMBO J 12: 4181–4189

  • Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG and Reed JC . 1994 Proc Natl Acad Sci USA 91: 9238–9242

  • Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M and Reed JC . 1997 Proc Natl Acad Sci USA 94: 5113–5118

  • Shao RG, Shimizu T and Pommier Y . 1997a Exp Cell Res 234: 388–397

  • Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW and Pommier Y . 1997b Cancer Res 57: 4029–4035

  • Singleton JR, Dixit VM and Feldman EL . 1996 J Biol Chem 271: 31791–31794

  • Thornberry NA and Lazebnik Y . 1998 Science 281: 1312–1316

  • Townsend KJ, Trusty JL, Traupman MA, Eastman A and Craig RA . 1998 Oncogene 17: 1223–1234

  • Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R and Glazer PM . 1997 Cancer Res 57: 3079–3083

  • Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ-Y and Yang-Yen HF . 1999 Mol Cell Biol 19: 6195–6206

  • Wang Q, Worlan PJ, Clark JL, Carson BA and Sausville EA . 1995 Cell Growth Diff 6: 927–936

  • Wong FH, Hu C, Chen SC, Yu YT and Chang C . 1992 Chinese J Microbiol Immunol 25: 59–68

  • Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME . 1995 Science 270: 1326–1331

  • Yang E and Korsmeyer SJ . 1996 Blood 88: 386–401

  • Yang T, Kozopas KM and Craig RW . 1995 J Cell Biol 128: 1173–1184

  • Yao R and Cooper GM . 1995 Science 267: 2003–2006

  • Zamorano J, Wang HY, Wang LM, Pierce JH and Keegan AD . 1996 J Immunol 157: 4926–4934

  • Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ . 1996 Cell 87: 619–628

Download references

Acknowledgements

We thank Dr Hsin-Fang Yang-Yen, Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, Dr Hsian-Fu Kung, NCI-Frederick Cancer Research and Development Center, Frederick, and Dr Melanie H Cobb, University of Texas, Southwestern Medical Center, Dallas, for their generously provided plasmids. We appreciate Dr Chi-Hung Lin, Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, for his excellent technical advice in the photography of double staining. We thank Ms Wen-Hsuang Fong for her assistance in the construction of mcl-1 antisense plasmid. We also thank Dr Chen-Kung Chou, Department of Medical Research and Education, Veterans General Hospital, Taipei, Taiwan and Dr Ming-Zong Lai, Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, for their inspirational suggestions. We thank Dr Jeou-Yuan Chen for her critical review and suggestions in the preparation of the manuscript and Ms Shiang-Lien Lu for her excellent secretarial assistance. This work was supported by the National Science Council, grants NSC86-2314-B-075-031, NSC87-2314-B-075-061, and NSC88-2314-B-075-013.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leu, CM., Chang, C. & Hu, Cp. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 19, 1665–1675 (2000). https://doi.org/10.1038/sj.onc.1203452

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203452

Keywords

This article is cited by

Search

Quick links